KIR3DL3/IL-2 Luciferase Reporter Jurkat Cell Line
Recombinant Jurkat cell line expressing firefly luciferase under the control of an IL-2-responsive promoter, and with constitutive expression of human KIR3DL3 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains and Long Cytoplasmic Tail 3; GenBank accession #BC143802.1 corresponding to KIR3DL3*00402 allele).
Interested in screening and profiling inhibitors, blocking antibodies, or activators of KIR3DL3 without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
Name | Ordering Information |
Thaw Medium 2 | BPS Bioscience #60184 |
Growth Medium 2P | BPS Bioscience #78354 |
Materials Required for Cellular Assay
Name | Ordering Information |
Anti-HHLA2(B7-H7) antibody1 | Bahatt, RS, et al., 2021 (see references) |
Growth Medium 2P | BPS Bioscience #78354 |
Assay Medium: Thaw Medium 2 | BPS Bioscience #60184 |
B7-H7(HHLA2)/TCR Activator CHO Cell Line | BPS Bioscience #78321 |
Anti-CD28 agonist antibody | BPS Bioscience #100186 |
96-well tissue culture treated, white clear-bottom assay plate | Corning #3610 |
ONE-Step™ luciferase assay system | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
HHLA2 (B7-H7) mediates an immune-stimulatory signal via TMIGD2 (Transmembrane and immunoglobulin domain containing 2; CD28H) in naïve T cells while it delivers an immune-inhibitory signal through KIR3DL3 in activated T cells and Natural Killer (NK) cells.
1. Bahatt RS, et. al., Cancer Immunol Res. 2021 Feb;9(2):156-169.